Antonio Guillem / Shutterstock.com
Biopharmaceutical company Omeros has hit its competitor Par Pharmaceutical with two lawsuits at US district courts over the drug company’s attempt to market a generic version of its Omidria (phenylephrine and ketorolac injection) product.
To access the full archive, digital magazines and special reports you will need to take out a paid subscription.
If you have already subscribed please login.
If you have any technical issues please email tech support.
For access to the complete website, archive, and to receive print publications, choose '12 MONTH SUBSCRIPTION'. For a free, two-week trial with full access, select ‘TWO WEEK FREE TRIAL’.
Omeros; Par Pharmaceutical; Par Sterile Products; Omidria; ANDA; US District Court for the District of New Jersey